Mark Dornan
Seminars
Wednesday 2nd December 2026
Selecting the Right Radiopharmaceutical CDMO to De-Risk Development, Scale Manufacturing & Support Long- Term Commercial Success
2:00 pm
- Evaluating how expertise in isotopes, development and validation, quality assurance, production, supply chain, and regulatory readiness should influence CDMO selection decisions across different stages of TRP development
- Assessing and addressing the operational risks associated with tech transfer and batch reproducibility when partnering with external manufacturing providers
- Determining which strategic considerations including scalability, geographic footprint, and isotope supply integration are most critical for supporting future clinical and commercial growth
Tuesday 1st December 2026
Reviewing the Manufacturing Innovations Enabling Commercial-Scale TRPs
2:30 pm
- Discussing how isotope expertise, hot-cell infrastructure, regulatory readiness and radiopharmaceutical-specific GMP capabilities should influence CDMO selection decisions across different stages of TRP development
- Overcoming the operational risks associated with tech transfer, batch reproducibility, scheduling constraints and limited radionuclide handling capacity when partnering with external manufacturing providers
- Navigating which strategic considerations including scalability, geographic footprint, analytical capabilities and isotope supply integration are most critical for supporting future clinical and commercial growth
